GoodRx Holdings reports Q2 results today with its short sellers in visible retreat — and the borrow market too loose to suggest any squeeze pressure is building.
Short interest has fallen sharply in the run-up. Positioned at 5.5% of the free float as of August 4, the short base has shed nearly 18% over the past month, with an accelerated 9.6% single-session drop on August 4 alone. Despite that direction of travel, the borrow market remains firmly relaxed: availability runs at 684%, meaning there are roughly seven shares available to borrow for every one currently lent out — well above any threshold that might constrain new shorts. Cost to borrow has risen about 31% over the past week, though at 0.64% annualised it remains negligible. Options positioning is only modestly cautious, with the put/call ratio at 0.24, slightly above its 20-day average of 0.22 but nowhere near the year's high of 0.32. The stock itself is up 7% over the past month to $3.27 after slipping 2% on Wednesday, hinting at some pre-earnings nerves at the margin.
The analyst debate captures a stock that has been through a meaningful de-rating and is now trying to find its floor. A wave of target cuts and two downgrades — from JPMorgan and Jefferies — came through in January and February, reflecting concern about GoodRx's competitive position and the trajectory of its prescription marketplace model. Since then, Citi and TD Cowen both raised targets to $4.00 in May after the Q1 print, a sign that the most recent quarterly data was well-received. The mean price target now sits near $3.21, just below the current price, suggesting the Street collectively has little upside priced in at these levels. Goldman Sachs remains a notable hold-out at Neutral with a $2.50 target — a notable gap below where the stock is trading. One genuine bright spot in the factor data: forward EPS growth ranks in the 95th percentile of the universe, a signal that consensus expects meaningful earnings recovery even if near-term surprise history is weak (EPS surprise ranks just 13th percentile).
Institutional ownership adds an interesting wrinkle. Francisco Partners holds nearly 18% of shares, and co-founder Trevor Bezdek still holds around 1.6%, with a small addition reported as recently as June. Insider activity from the CEO and CFO in July consisted entirely of routine award-and-sell patterns — equity compensation vesting followed by immediate tax sales — carrying no directional signal. One historical data point worth noting: the last earnings event in June produced a 4.4% one-day drop followed by a further drift lower, while the May 2026 print sparked a 13.6% one-day gain before fading over the following week. That asymmetry illustrates how binary the reaction function has been.
Today's print will test whether the Q1 re-acceleration in earnings expectations was durable or a one-quarter reprieve — and whether the retreating short base reflects genuine improving fundamentals or simply short sellers taking profits ahead of a potentially volatile release.
See the live data behind this article on ORTEX.
Open GDRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
